A Phase II study of Sorafenib (BAY 43-9006) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC) Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Chen, E
  • Winquist, E
  • Agulnik, M
  • Chin, S
  • Pond, Gregory
  • Cheiken, R
  • Francis, P
  • Petrenciuc, O
  • Siu, L

publication date

  • October 1, 2005